• The prevalence of ROS1 rearrangement in NSCLC is 1%-2% 18

Tests that can identify ROS1+ NSCLC

FISH=fluorescence in situ hybridization; IHC=immunohistochemistry; NCCN=National Comprehensive Cancer Network®; NGS=next-generation sequencing; RT-PCR=reverse transcription polymerase chain reaction.

Available NGS platforms for ROS1 testing include:

  • The list provided below may include some tests that are not FDA approved. Contact the individual lab for more information regarding a specific test. This list is non-exhaustive and is not intended to be a recommendation or endorsement of a specific laboratory or test

Cancer Genetics Incorporated

Caris Life Sciences

Foundation Medicine

Integrated Oncology

Intermountain Precision Genomics

Knight Diagnostic Laboratories, Oregon Health & Science University

Mayo Clinic Laboratories

NeoGenomics Laboratories

Paradigm Diagnostics, Inc.

PathGroup

List is current as of August 2019.

ROZLYTREK Efficacy in ROS1+ Patients

Efficacy in ROS1+ mNSCLC Patients

View efficacy data in ROS1+ patients

ROS1+ Study Design

ROS1+ mNSCLC Study Design

Learn how ROZLYTREK™ was studied in ROS1+ patients

ROZLYTREK Financial Resources

Financial and Other Resources

Learn more about financial and other resources for ROZLYTREK